18.12.2024
Antibodies as ion channel modulators and drugs
In his third preclinical ion channel drug discovery blog, Marc Rogers explores the evolution of antibodies as ion channel modulators, highlighting breakthroughs in monoclonal antibodies, nanobodies, and antibody-toxin chimeras across immunology, cardiology, neuroscience, and oncology. Key case studies include Kv, Nav, Cav, TRP channels, and GPCR targets revealed through manual and automated patch clamp technologies.
After academic research as a neuroscientist and 20 years of commercial ion channel drug discovery, Marc Rogers now works as a freelance blogger, advisor and consultant for clients in the UK, EU and US where he shares his expertise and enthusiasm for all aspects of ion channel screening. He is particularly interested in automated patch clamp, and exploiting the potential of human iPS stem cell assays to facilitate the successful translation of new drugs into the clinic.
With the ongoing shift in clinical therapeutics from small molecules to biologics, now is the perfect time to dive into the evolution and current status of antibody ligands as ion channel modulators. This comprehensive review examines efforts in academia and industry to develop polyclonal and monoclonal antibodies, single-domain nanobodies, and antibody-toxin chimeras. These innovations are advancing preclinical research in immunology, cardiology, neuroscience, and oncology.
Highlights include case studies on antibodies targeting Kv, KCa, K2P, Kir, Nav1.x, Cav, TRPx, P2X, ASIC, and Orai channels. Functional insights from manual and automated patch clamp (APC) electrophysiology showcase their potential. Building on over 25 years of research, this blog offers a fresh update with the latest publications and commercial developments.
